Helixgate https://validator.w3.org/feed/docs/rss2.html Metabolomics reveals how tubuloside A inhibits Streptococcus suis biofilms Garlic compound blocks key signal, triggering gastric cancer cell death New machine learning model predicts IVIG resistance in Kawasaki disease Novel kynureninase inhibitor KS79356 slows triple-negative breast cancer progression Emotional Changes in Chronically Ill Patients After a Complementary Therapy Support Program Machine learning and free energy methods discover new tuberculosis KasA inhibitors Multiomics reveals SYNPO2/VNN1 target and microbiota vaccine for atherosclerosis Staff perspectives shape cross-sector care for dual diagnosis patients Treating osteoporosis in older men: review of drug and lifestyle trials Engineered GITR antibody boosts CD4 T cell-dendritic cell teamwork against tumors MCC protein links Wnt signaling to blood vessel polarity and remodeling Enhanced INFO algorithm enables multi-threshold segmentation of colorectal cancer histopathology images 1,5-Pentanediamine from CRKP-colonized patients weakens CD19 CAR-T cells in vitro French expert consensus on cladribine tablets for relapsing MS beyond year 4 Machine learning predicts CDK4/6 inhibitor outcomes in metastatic breast cancer Whole-genome sequencing reveals genetic predictors of rifabutin susceptibility in multidrug-resistant tuberculosis Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review Replimune’s melanoma drug would have been rejected again if not for senior CBER official TScan axes 75% of workforce, prioritizes solid tumor program Biotech is back, with H1 progress smoothing glide path through end of year: Truist Pfizer punts Seagen ADC, further muddying value of the $43B buyout AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease TScan cuts 75% of workforce while shifting focus to solid tumor program RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer US to grant up to $125M for personalized RNA manufacturing innovation Breaking borders: Building biotech scale in Benelux Biopharma needs more data scientists. Who’s getting hired? Capricor, Replimune illustrate why FDA must listen to rare disease specialists FDA raises bar for foreign site inspections as China trials surge Follow the money: How funding announcements can help identify jobs before they’re posted UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines Trailing rivals, AbbVie scores win with dual-acting myeloma drug This week in charts: China deals, stock flatlines and Lilly’s M&A spree Ionis’ rare neurology drug approved; Pfizer inks an ADC deal An AI drug specialist zeroes in on rare forms of obesity GSK wagers up to $1.3B on a different kind of cancer drug Akeso, Summit cancer drug confirms lung cancer survival benefit The hidden scale-out problem behind CAR-T’s growth Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study STAT+: FDA takes another look at botanical drugs STAT+: Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder STAT+: Seattle scientists launch $95 million AI biology effort STAT+: Abivax has still not been acquired. What’s going on? Opinion: STAT+: A surprising bright spot at the FDA on regulating unproven stem cells STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial Home